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Proteinase-activated receptor 2 (PAR2) is a cell surface receptor activated by serine proteinases or specific synthetic compounds.
Interest in PAR2 as a pharmaceutical target for various diseases is increasing. Here we asked two questions relevant to endothelial
dysfunction and diabetes: How is PAR2 function affected in blood vessels? What role does PAR2 have in promoting obesity,
diabetes, and/or metabolic syndrome, specifically via the endothelium and adipose tissues? We conducted a systematic review of
the published literature in PubMed and Scopus (July 2015; search terms: par2, par-2, f2lr1, adipose, obesity, diabetes, and metabolic
syndrome). Seven studies focused on PAR2 and vascular function. The obesity, diabetes, or metabolic syndrome animal models
differed amongst studies, but each reported that PAR2-mediated vasodilator actions were preserved in the face of endothelial
dysfunction. The remaining studies focused on nonvascular functions and provided evidence supporting the concept that PAR2
activation promoted obesity. Key studies showed that PAR2 activation regulated cellular metabolism, and PAR2 antagonists
inhibited adipose gain and metabolic dysfunction in rats. We conclude that PAR2 antagonists for treatment of obesity indeed show
early promise as a therapeutic strategy; however, endothelial-specific PAR2 functions, which may offset mechanisms that produce
vascular dysfunction in diabetes, warrant additional study.
1. Introduction
Obesity, diabetes, and metabolic syndrome are risk factors
for cardiovascular disease. Insulin resistance and high blood
glucose levels can lead to endothelial dysfunction, a cardio-
vascular complication of these dysmetabolism states and a
common pathology of cardiovascular disease [1]. Endothelial
dysfunction impairs regulation of vascular smooth muscle
tone and vasodilation, which reduces oxygen supply and
inhibits the capacity of tissues and organs to meet changes
in metabolic demand [2]. Improving cellular metabolism
and preserving, restoring, and/or rescuing endothelial cell-
regulated vascular functions like vasodilation are desirable
features for new therapeutics.
This study is a systematic review of the literature provid-
ing evidence that proteinase-activated receptor 2 (PAR2) is
involved in obesity, diabetes, and metabolic syndrome. PAR2
is a cell surface receptor that is activated by endogenous
serine proteinases or pharmacologically by synthetic ligands
(Figure 1) [3, 4]. On the one hand, PAR2 activation could
preserve blood flow associated with specific endothelial cell
mechanisms; on the other hand, PAR2 activation could also
stimulate inflammation pathways, which may impair cellular
metabolism, produce insulin resistance, and promote obesity
and diabetes [5]. Our objective for this review was to gain
a better understanding about PAR2 effects—especially its
activation versus inhibition—in studies of obesity, diabetes,
and metabolic syndrome. Two specific questions were asked:
How is PAR2 function affected in blood vessels? What
role does PAR2 have in promoting obesity, diabetes, and/or
metabolic syndrome, specifically via the endothelium and
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Figure 1: Activation of protease-activated receptor 2. (a) PAR2 is a seven-transmembrane domain cell surface receptor that can be activated
by serine proteases which recognize a substrate sequence on the N-terminus (-NH
2
) located in the extracellular space. To highlight the
uniquemechanism of action a simplified cartoon shows the arrangement of the nonactivated PAR2 protein sequence (ribbon) in a cell plasma
membrane. Asterisk indicates the site of proteolytic cleavage ofmouse and rat PAR2 associatedwith serine proteases, including trypsin, human
mast cell 𝛽-tryptase, matriptase, and several human kallikreins. (b) Following proteolytic cleavage, the newly revealed N-terminus (shown
as LRGILS) acts as a tethered ligand that interacts (solid arrow) with the extracellular loop-2 (ECL-2) domain and induces the activated
state of the receptor. Alternatively, receptor activating peptides (2fLIGRLO, SLIGRL, and SLIGKV), and nonpeptide agonists (GB110) can
activate PAR2 without the participation of proteases (dashed arrow). Also, shown are the proposed sites of action of different classes of
PAR2 antagonists, that is, GB83, GB88 (dashed arrow) and PAR2 pepducin P2pal-14GQ (oval arrow). Peptide sequences are identified by
their amino acid sequences using the standard capitalized one-letter abbreviations. All PAR2 activating peptides were synthesized as amides.
Sequence starting with 2f indicates N-terminal modification with a 2-furoyl functional group. COOH: carboxy terminus; ECL: extracellular
loops domains 1 to 3; ICL: intracellular loop domains 1 to 3; TM: transmembrane loop domains 1 to 7.
adipose tissues? This review identifies current trends and
knowledge gaps about PAR2 actions in obesity, diabetes, and
metabolic syndrome. Addressing these gaps may improve the
strategies to address obesity and/or diabetes or raise impor-
tant issues to be addressed as pharmaceutical development
proceeds with PAR2-based drugs.
In the vasculature, PAR2, a seven-transmembrane class-
A GPCR [6], is constitutively expressed in endothelial cell [7]
and inducible in endothelial cell and vascular smooth muscle
cells [8, 9]. The canonical description for the mechanism
of PAR2 action is that specific PAR2-activating compounds
and serine proteinases activate Gq-alpha, which via phos-
pholipase C activity increases intracellular IP3 and activates
IP3R and results in the release of internal stores Ca2+ as
shown in [10]. PAR2 signal transduction mentioned above
is recognized as being more complex (reviewed in [11]) than
a single agonist-receptor pathway. Thus, PAR2 signalling by
the internalized receptor [12], transactivation of other recep-
tors [13], subcellular localized receptor distributions [14],
tethered-ligand disarming [15], and agonist-biased signals
[16] contribute to a complex system of PAR2 mediated cell
responses.
Serine proteases like trypsin [4, 17] and human mast
cell 𝛽-tryptase [18], matriptase [19], and several isoforms
of human kallikreins [20] activate PAR2 by a mechanism
involving a self-contained tethered ligand (Figure 1) [6],
which is produced by proteolytic cleavage within a specific
sequence of PAR2’s amino terminus and binds to sites in
its extracellular loop 2 domain [21]. Nonserine proteases,
including elastase and cathepsin S, have also been reported
to recognize substrate sequences within the N-terminus of
PAR2 and thus produce alternate truncated extracellular N-
terminus [15, 22]. Some of these truncations will effectively
disarm the receptor by removing the region used for activa-
tion by other proteases and other truncations may induce an
activation of PAR2 signal transduction [23].
A broad range of pharmacological tools (Figure 1) are
available for examining PAR2 (reviewed in [24]), including
PAR2-activating peptides [25–28], small molecule PAR2
agonists [29–32] and antagonists [33, 34], cell permeable
pepducins [35], and anti-receptor antibodies [36]. PAR2-
activating peptides are short peptides synthesized to match
the N-terminal amino acid sequence of the PAR2 tethered
ligand revealed by trypsin and trypsin-like serine proteases
[27]. For example, SLIGKV and SLIGRL match the N-
terminus sequences of human and rodent (mouse and rat)
PAR2, respectively [26]. Modifications (e.g., substitutions
and additions) to the synthetic PAR2-activating peptides
change the potency, increase in vitro resistance to peptidases,
and provide sites to tag with labels for ligand-binding [37]
and receptor visualization studies [38]. 2-Furoyl-LIGRLO
(2fLIGRLO) is one example of a compound derived from
the template SLIGRL and is the most potent PAR2 peptide
agonist in use since its discovery [28]. GB110 is a nonpeptide
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compound with good potency and selectivity for activating
PAR2 [29, 33]. Researchers examined the effect of changing
the carboxy-terminus of GB110 to different spiropiperidines
and as a result identified two compounds, GB83 and GB88,
which are selective and potent inhibitors of PAR2-activation
by either activating peptides or serine proteases [33]. This
distinction was particularly notable because another PAR2
antagonist, ENMD-1068, inhibited only enzyme activation of
PAR2 [39]. GB88 administered in vivo reduced inflamma-
tion in various models of inflammation [40, 41]. However,
the more recent study provides evidence that GB88 is a
selective antagonist of PAR2-mediated intracellular calcium-
release and a partial agonist of other PAR2-mediated signal
transduction, for example, ERK phosphorylation [41]. A
separate group of researchers has developed a different PAR2
antagonist, C391, which blocked multiple PAR2-mediated
cell signaling pathways [34]. A different technology strategy
for pharmacological inhibition of PAR2 is the development
of pepducins, which are a class of lipid soluble peptide
compounds that target the intracellular regions ofGPCR [42].
PAR2 pepducins (e.g., P2pal-21F and P2pal-18S) are amino-
terminus palmitoylated peptides that use the intracellular
loop three of PAR2 as a template amino acid sequence
[35]. P2pal-21F is a nonselective agonist of PAR2 and PAR1
whereas P2pal-14GQ is a selective antagonist of PAR2 [35].
P2pal-14GQ is the most potent of a series of PAR2 pepducins
that inhibited PAR2-mediated cell signaling and was anti-
inflammatory in a PAR2-depenent inflammation model [35].
In endothelial cells, PAR2-mediated Ca2+-release acti-
vates nitric oxide synthase [25] andCa2+-activated potassium
channels [43], relaxes vascular smooth muscle, dilates arter-
ies, increases tissue perfusion, and lowers blood pressures
[44]. Yet in contrast to these potentially beneficial effects
on cardiovascular function, studies have provided evidence
demonstrating PAR2 activation can promote inflammation
responses, for example, by inducing cytokine release [19] and
adhesionmolecule expression [45]. However, PAR2mediated
pathophysiology is not associated with any singular serine
proteinase, which would appear to leave a wide scope of
potential roles for the receptor and potential mediators in
obesity, diabetes, and metabolic syndrome.
2. Methods
Studies were selected for review by searching PubMed and
Scopus databases (last search updated July 2015). In one
arm of the search, the terms were ((par2 or par-2 or
f2rl1) endothelium) and (diabetes or obesity or adipose or
metabolic syndrome). PAR2 and PAR-2 have been more
commonly used than f2rl1 (factor 2 receptor like 1), which
is the most recent name assigned to the gene encoding
PAR2 and highlights the gene homology shared with factor 2
receptor (f2r1, PAR1, or the thrombin receptor). In the other
arm of the search, the keywords were ((par2 or par-2 or f2rl1)
and (diabetes or obesity or adipose or metabolic syndrome)
not endothelium. These searches produced 10 and 35 results.
Three additional studies were identified by citations in the
search articles. Each study was abstracted and reviewed for
relevance and, subsequently, content. Tables 1 and 2 list all the
included studies from first [46–48, 50–53] and second arm
[54–60, 62–67], respectively. Reviews, editorial articles, and
papers that did not pertain to protease-activated receptors
or deemed to have peripheral or limited direct relevance to
diabetes, obesity, or metabolic syndrome were excluded from
further study.
3. Results
3.1. PAR2 Endothelial Cell Mechanisms in Obesity, Diabetes,
and Metabolic Syndrome. PAR2 expression on endothelial
cell [7] and adipocytes [48] is constitutive. Inflammatory
mediators [68] and dietary fatty acids [63] can induce PAR2
expression in endothelial cells and adipocytes, respectively.
From separate studies, it is known that PAR2 activation by
specific activating compounds and enzymes cause endothe-
lial cell-mediated vascular smooth muscle relaxation, dilate
blood vessels, increase blood flow, and lower blood pressures
[44].
All studies listed in Table 1, except for a single study [48]
reported PAR2-mediated relaxations of blood vessels that
were preserved or increased in animals with obesity [53],
diabetes (type 1 [46] or type 2 [47, 50, 51]), or metabolic
syndrome [52]. These results on their own suggest that PAR2
activation may preserve local or regional blood flows in the
face of endothelial dysfunction. The shared result is inter-
esting because several different rodent models associating
endothelial dysfunction with metabolic status were utilized.
In these studies, PAR2was comparedwithmuscarinic [46, 47,
50–52] or bradykinin [53] receptor mechanisms of vasodila-
tion; both ofwhichwere impaired, consistentwith their use as
internal references for endothelial dysfunction in these mod-
els. Unfortunately, Li et al. [48] did not provide data to allow
comparison of PAR2 endothelial cell-mediated vasodilation
between healthy (C57B6) and noninsulin dependent diabetes
models (type 2; TallyHo mice). The cellular (endothelial cell
versus vascular smooth muscle cell) and subcellular mech-
anisms explaining the PAR2 mediated relaxations vary—for
example, nitric oxide [47, 50, 52], cyclooxygenases [46, 50]
or Ca2+-activated K+ channels [51, 53] have been inferred
as primary mediators—between studies. Differences in the
choices of experimental models and types of blood vessel
preparations (aorta [46, 47], coronary arterioles [50], small
mesenteric artery branches [51, 52], middle cerebral artery
[53], and superior-mesenteric artery [52]) may contribute to
some of the mechanistic variations between each study.
In the studies listed in Table 1, all of the experimental
group animals displayed elevated blood glucose [47, 48, 50,
51, 53] and or urine glucose [46, 51, 52] levels, consistent
with the premise of metabolic dysregulation. In two of
the four studies with type 2 diabetes models, the diabetic
animals (db/db mice) were obese and weighed more than
lean controls [50, 51]. Glucose intolerance, high levels of
serum insulin and blood lipids, larger body masses, and high
systolic arterial blood pressures were confirmed in the rat
model of metabolic syndrome [52]. Underlying causes of
hyperglycemia, insulin resistance, and/or obesity included
genetic propensities for type 1 [46] and type 2 diabetes [47, 48,
50–52] and a high-fat high-carbohydrate diet [53]. As shown
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in Table 1, the metabolic phenotypes of the experimental
groups were broadly categorized: nonobese diabetic [46, 47],
obese diabetic [48, 50, 51], diet-induced obesity [53], and
metabolic syndrome (high blood pressure [52]). One study
[52] examined the reversal of hypertension and elements of
endothelial dysfunction on PAR2 and blood vessel function
after treatment of animals with telmisartan, an angiotensin-
II type 1 receptor antagonist. Two studies by independent
research groups [50, 51] examined obese diabetic db/db
mice. However, each group looked at outcomes in different
vasculatures. Treatment in vivo with a putative PAR2 antag-
onist peptide reportedly reversed endothelial dysfunction
in the coronary vasculature of the db/db [50]. Each of
the other studies in Table 1 used a different experimental
model; some models produced similar metabolic pheno-
types despite being based in different species or strains of
rodents.
Only two studies reported using nonobese diabetic ani-
mals to study PAR2 in the vasculature. These studies found
the same trend for sustained PAR2 vasodilation [46, 47]. In
nonobese type 1 diabetic female mice [46], PAR2 mediated
dilations of aortas were preserved by an increased release
of COX-2 dependent prostaglandins. By comparison with
another nonobese rodent model of type 2 diabetes, male
Goto-Kakizaki rats [47], a cyclooxygenase inhibitor had no
effect on PAR2 mediated relaxation of the superior mesen-
teric artery; the proposed explanation was an increase in
PAR2 expression that compensated for decreased vasodila-
tor mediators. No direct comparisons between obese and
nonobese diabetic models have been reported.
Age-dependent outcomes were assessed in a few studies
as a part of the model employed [46, 52, 53]. In such cases,
time-course changes in the sensitivity to PAR2 appeared to
increase with the progression of the metabolic disease [46,
52, 53]. Within the studies listed in Table 1, the effects of sex
on PAR2-dependent responses in blood vessels have not been
examined; most of the studies exclusively used male animals
[47, 51–53]. Indeed the few studies that included female
subjects did not account for sex in reporting or analyzing data
[46, 48, 50]. All studies in Table 1 were conducted in rodents.
Mouse strains included CD-1, FVB/N, and NOD/Ltj [46];
TallyHo [48]; C57BL6 [48, 51]; rat strains includedWistar [47,
52] and Sprague-Dawley [53]. Organ bath [47, 52] and small
wire-myograph [46, 48, 51] bioassay methods outnumber the
isolated perfused vessel preparations [50, 53] for assessing
endothelial function in blood vessels. Endothelial function
was measured in all cases by the reversal of blood vessel
constriction, using pretreatment with agonist that varied
in each preparation. PAR2-activting peptides, SLIGRL [46–
48, 53] or 2fLIGRLO [48, 50–52], were used as agonists for
PAR2 activation. Only one study [51] also used trypsin, a
serine protease that activates PAR2 at low concentrations and
PAR1 at high concentrations. Similarly only Li et al. [48]
examined blood vessel function with PAR2 in the presence
of perivascular adipose tissue, identifying adipose-derived
relaxing factors elicited by PAR2 agonist (SLIGRL). Interest-
ingly, the PAR2-inactive peptides (LRGILS and 2fOLRGIL)
caused a PAR2-indepdent release of a pharmacologically
distinct adipose-derived relaxing factor [48].
In a couple of studies [46, 50], immunohistochemistry
data provided preliminary qualitative evidence corroborating
the increased expression of PAR2 within the selected blood
vessel. Quantifying PAR2 expression in tissues has been prob-
lematic because the same tools (antibodies) used in Western
blot methods demonstrated evidence of off-target signals [51,
69] and, thus, challenge the validity of concluding that PAR2
expression increased [46, 47, 50]. Quantitative real-time PCR
has been used to assess par2 gene expression [51, 52] and is
indirect evidence of protein expression. In general, evidence
of the subcellular distribution of PAR2 within endothelial
cells of the vessels is lacking in these studies, but based
on functional studies (i.e., removing the endothelium and
using genetic PAR2 knockouts) the expression of PAR2 in
endothelial cells is critical to the blood vessel function in all
except two studies [46, 48]. However, between these latter
studies, only Roviezzo et al. [46] compared endothelial cell-
mediated vasodilation by PAR2 between the healthy and
disease states. Previously, the other investigators provided
evidence of endothelial dysfunction in aortas of TallyHo
mice, based on experiments using only acetylcholine as the
primary agonist [49].
Metabolic syndrome was examined in a single experi-
mentalmodel [52] that combined high arterial blood pressure
with the altered metabolic parameters. This SHRSP.ZF rat
model points to sustained nitric oxide-mediate mechanisms
underlying PAR2 activation of arteries [52]. Interestingly,
angiotensin-II receptor 1-antagonist treatment in this same
model did not affect the sustained PAR2 mechanism and
restored function to other endothelial cell agonists by reestab-
lishing nitric oxide-mediated vasodilation [52]. A number
of factors in this model, including age, sex, and disease
progression, warrant further study to delineate the regulation
of PAR2 under the conditions of metabolic syndrome. This
model [52] in particular may be useful for following up the
cardiometabolic consequences of PAR2 function inferred by
the studies in Table 2.
3.2. PAR2 Signalling Mechanisms in Obesity, Diabetes,
and Metabolic Syndrome
3.2.1. Experimental Models. As summarized in Table 2,
researchers have applied separately in vitro and in vivo
methodologies for examining the role of PAR2 signalling in
obesity and diabetes, outside of the context of endothelium
function [54–60, 62–67]. Overall, there is a trend of finding
increased PAR2 expression in tissues from obese humans
[63] and rodents, which included obesity with or without
diabetes. Causes of obesity and diabetes in these models
included genetic mutations [56, 58, 59], high fat diets [57,
67], or T cell mediated pancreatic islet destruction [55]. In
some but not all studies, the increases in mRNA expression
or immunospecific staining of tissues were corroborated by
functional responses to agonists of PAR2 [54–56, 60, 63].
PAR2-activating peptides (2fLIGRLO [56, 63], SLIGRL [54,
55, 63], and SLIGKV [64, 65]) were more commonly used as
agonists, with fewer studies having used trypsin activation of
PAR2 [54, 60, 64]. Interesting trends in the research themes
include studies of transactivation of PAR2 by cell specific
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receptors, for example, the cytoplasmic tail of tissue factor
[57, 67] or epidermal growth factor receptor, and the regu-
lation of metabolic pathways by PAR2, for example, AMP-
activated kinase [56, 57, 67]. Such research seeks answers to
address the question of how PAR2 is linked to regulation
of cell metabolism and proposes novel interactions between
metabolism and the immune system.
There is an increasing trend in the field of PAR research
towards identifying novel activation pathways by endogenous
proteases or nonserine proteases [58, 64, 65]. Studies listed
in Table 2 have provided relatively weak evidence for any
relationship between a specific protease [58, 64, 65] as being
an endogenous mediator of PAR2’s role in diabetes and
obesity. As we found with the studies of PAR2 with the
vasculature, the studies [54–60, 62–67] listed in Table 2 have
not systematically investigated age- or sex-related differen-
ces.
3.2.2. Signalling Pathways Differences/Heterogeneity. As
shown by examples cited in this review, PAR2 intracellular
signalling pathways vary by cell type and experimental
conditions. Indeed the selectivity of activators for PAR2
Ca2+-dependent versus Ca2+-independent signaling has
been proposed as an explanation differentiating actions
of PAR2 by different enzyme agonists [70]. Recent studies
indicate distinct roles for regulation of gene expression
by PAR2 based on whether it is localized at the plasma
membrane versus the cell nucleus [14, 71]. Thus, recognition
of PAR2 agonist-biased signalling is warranted for future
studies that examine this receptor in disease models
and consider the therapeutic potential of various PAR2
modulating compounds.
Blocking PAR2 signalling with small molecule antago-
nists and antibodies has been tested and resulted in reducing
or normalizing adiposity and some metabolic parameters in
the obesity models [57, 63, 67]. In one case using the diet-
induced obesity/metabolic syndrome rat model [63], supple-
mentary data provided evidence that GB88, a biased PAR2
antagonist, treatment blunted the effect of HCHF-feeding on
several indices of cardiac function and the interstitial collagen
content in the left ventricular myocardium; however, cardiac
output was not different between controls and treatments.
Systolic blood pressures of HCHF + GB88 group were less
(∼10%) than HCHF alone. Further examination of GB88
action in vivo when placed in combination with selective
PAR2 antagonists, for examples, pepducin P2pal-14GQ [35],
could provide further insight into cellular mechanisms. Stud-
ies in par2 knockout mice indicated eliminating par2 func-
tion had a modest effect on raising systolic blood pressures
[72] and, thus, may counter the benefits of lowering the rate
of adiposity gain under a high fat diet. Integrating the models
of PAR2 function in the vasculature with its concomitant
actions elsewhere, which promote obesity, is a logical step
toward a better understanding of the balance of PAR2
therapeutics for metabolic dysfunction and cardiovascular
risk.
4. Discussion
We conducted this review in order to evaluate the role of
PAR2 in obesity, diabetes, and metabolic syndrome as well
as identifying trends in this research field. We found that
PAR2 was linked to obesity, diabetes, and metabolic syn-
drome by two separate, but not mutually exclusive research
themes, whichwe identified by their focus onPAR2-mediated
endothelial cell functions or not.This division of the literature
along two themes is relevant because endothelial dysfunction
is a characteristic factor of cardiovascular complications in
diabetes. Strategies for pharmaceutical interventions target-
ing PAR2 should account for both vascular function and
metabolism effects in diabetes.
The first theme we identified in the literature centers on
the role of PAR2 on endothelial cells and their function or
dysfunction in regulation of circulatory control in metabolic
syndrome obesity and or diabetes [46–48, 50–53]. In these
studies, a case is made for the presence of sustained PAR2
mediated vasodilation in the diabetic, obese, or metabolic
syndrome state that is consistent with the broader literature
about preserved PAR2 functions on arterial vasculature, for
example, in other models of circulatory diseases, conditions
(ischemia), and injury [45, 51, 73–79]. Under this theme,
studies focused on the functional local consequences of
PAR2 activation on blood vessels and strategies have applied
various rodent models [46–48, 50–53]. Tissue responses to
PAR2 activation are assayed by the endothelium dependent
or independent mechanism in the functional responses of
blood vessels [46–48, 50–53]. These studies vary by the age
of animals, sex, species, and the vessel types (Table 1). In
some cases the mechanisms are explored and the mediators
of the pathways include nitric oxide, cyclooxygenases, and
endothelium-dependent hyperpolarization [46–48, 50–53].
A development in the literature is a role proposed for PAR2
as a regulator of vascular tone via perivascular adipose tissue,
specifically via adipocytes [48]. Others reported finding
PAR2 expression in a nonadipocyte fraction of PVAT, which
included infiltrating immune cells [63]. PAR2 differentiates
from other GPCR by its activation of paracrine factors from
perivascular adipose tissue that affect function of the blood
vessels [48]. Such studies bridge a blood vessel-centered focus
on circulatory function with evidence that PAR2 plays a role
in inflammation pathways that link tometabolic dysfunction,
outlined in the next section.
In the second theme, researchers have focused onmodels
residing primarily outside of the endothelial cell domain
[54–60, 62–67]. These studies have provided insight into
detailed intracellular signalling mechanisms that build a case
for PAR2 promotion of obesity. A developing trend in this
theme is a divergence on the focus of PAR2 regulation
mediated solely by pairing of GPCR with an agonist; rather
studies present PAR2 as a coreceptor associated with the
complex signaling by other receptors, for example, by the
cytoplasmic domain of tissue factor [57, 67]. Along a similar
line, investigators are examining PAR2 modulation of cell
functions mediated via 𝛽-arrestin dependent mechanisms
[56]. Converging evidence points to a common pathway of
12 BioMed Research International
AMPK regulation by PAR2 that can be modulated by 𝛽2-
arrestin expression [56, 57, 67]. Demonstrating PAR2 is a
modulator AMPK, a key regulator of cell metabolism, is
a significant advancement in understanding its effects on
energy regulation in the whole organism and supports the
notion of interventions based on PAR2 [57, 63, 67]. Strategies
have used amix ofmethods, ranging from in vitro cell culture
studies, including human pancreas islet-derived precursor
cells [54] and adipocyte-derived stem cell lines [60, 61] to
gene transcription association studies in humans [62]. No
evidence has been provided to indicate that regulation of
endothelial cell-specific expression or activity contributes
directly to the pathology of obesity, diabetes, or metabolic
syndrome.
In regards to obesity, diabetes, and metabolic syndrome,
there has been speculation that dipeptidyl peptidase-4 (DDP-
4) [65] and chitinase-3 like protein 1 (CH3L1) [64] activate
PAR2.However, weaknesses identified in Table 2 raise serious
doubts about either of these proteins modulating specifically
PAR2. More broadly the literature supports the notion that
activation of PAR2 is not mediated by a single proteinase but
is dependent on the protease network of local environments.
It is unclear how exposure to proteases from food plants [58]
fits into PAR2 regulation of metabolism or cardiovascular
function. In theory, specific proteases couldmediate different
functions based on the tissue examined or its health state.
In separate studies, some kallikreins were shown to activate
PAR2 [80] and the kallikrein-kinin system is associated
with the pathophysiology of diabetes, mostly by mechanisms
involving bradykinin (reviewed in [81]). Cultured aortic
vascular smooth muscle cells, but not endothelial cells, have
been shown to activate plasma prekallikrein and stimulate
PAR2 and epidermal growth factor receptor transactivation
[82]. There is a current gap in direct evidence linking PAR2
to the kallikrein-kinin system in the pathophysiology of
diabetes. However, the expression of PAR2 in tissues and
organs (kidneys) susceptible to damage in diabetic humans
[66] strengthens the rationale for further studies.
There have been few investigations conducted in humans
that have found a relationship between PAR2 and obesity. A
screening of thousands of single nucleotide polymorphisms
in African Americans found a positive correlation between
body mass index (BMI) and a PAR2 polymorphism [62]. In
a separate small study, PAR2 mRNA expression in adipocyte
tissues correlatedwith increasing the BMI of volunteer people
[63]. Replication of these findings in other populations and
identifying mechanisms underlying the single nucleotide
polymorphism and activating agents would provide better
understanding of scope of the impact on obesity and the
significance if any for development of therapeutics targeting
PAR2.
PAR2 is novel with regards to its response to vascular
disease and is a pharmaceutical drug target. Vascular dys-
regulation is a common consequence of metabolic diseases,
and new treatments are a priority for development. However,
our understandings about PAR2 mechanisms in diabetes,
obesity, and metabolic syndrome are based on preclinical
laboratory models, which have included both type 1 and type
2 diabetic models. A point of controversy is whether PAR2
activation promotes obesity and, thus, further dysmetabolism
in humans, because its expression correlated with BMI and
at least in animal models, blocking PAR2 activity reduced
adiposity and weight gain [57, 63]. Investigations conducted
in humans indicate that PAR2-activating peptides increase
forearm blood flow by arterial and venous dilation and
were well-tolerated by volunteers [83, 84]. The discovery
and development of new molecules to target PAR2 have
been accelerating [24]. As newer agonist and antagonists of
PAR2 [31, 34, 85] become available to researchers, the clinical
potential of such compounds will become more clear.
In preparation of this review,we strived to comment on all
published peer-reviewed articles relating to PAR2 in obesity,
diabetes, and metabolic syndrome.The authors acknowledge
that these metabolic conditions and their complications are
complex and involvemany physiological systems. By focusing
on the direct vascular actions of PAR2 and the implications
for cardiovascular complications, we have not commented
on the potential contributions of PAR2 to other related
complications through other mechanisms and systems, for
example, neuropathy and pain [86], itch [87], and dermatitis
[88].This review is intended to provide interested researchers
with a summary of the models and experimental approaches.
In an attempt to summarize diverse studies, some details that
make each piece of work unique have been omitted. However,
there are editorials and reviews focused on specific articles
cited in the review, for example, [5, 89], which can offer
interested readers alternative insights.
5. Conclusions
PAR2 activation can produce endothelial cell specific regu-
lation of vascular function in the face of obesity, diabetes,
and metabolic syndrome. There is yet no evidence directly
linking endothelial cell-specific PAR2 to obesity, diabetes, or
metabolic syndrome. However, PAR2 expression is observed
within other target tissues that could regulate vascular func-
tion, for example, perivascular adipose tissue. In general the
role of PAR2 in producing obesity, diabetes, and metabolic
syndrome has been investigated entirely independent of the
function of the vascular system and supports the devel-
opment of pharmaceutical antagonists of PAR2. However,
further research is needed to investigate the mechanisms
underlying PAR2 function in the vasculature and interaction
with pathophysiology in metabolic diseases, especially the
role of endothelial PAR2, which may be able to rescue
vascular health.
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